Nasdaq · CIK 0001736243
ACXP Acurx Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Apr 22, 2026. Close $1.27 on Oct 9, 2026, +2% from the 52-week low and -83% from the high.
Acurx Pharmaceuticals, Inc. (ACXP) has 17 SEC Form 4 filings on file from 8 insiders, the latest filed on Apr 22, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
6 open-market trades have been scored at ACXP. The newest: Jack H Dean (director) bought $10,000 of stock on Jan 6, 2025, filed Jan 8, 2025, scored 40 (moderate). The largest of the 6 shown: Robert J Deluccia (director and 10% owner) bought $50k on Jan 6, 2025, scored 40 (moderate). 6 insiders bought within 14 days of each other around Jan 6, 2025.
ACXP closed at $1.27 on Oct 9, 2026, 2% above its 52-week low and 83% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Acurx Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Jack H Dean director buy | $10,000 9,852 shares | +83% | - | |
| 40Moderate | Robert J Deluccia director, owner buy | $50k 49,261 shares | +5% | - | |
| 40Moderate | James J. Donohue director buy | $10,000 9,852 shares | +79% | - | |
| 47Moderate | David P Luci President and CEO buy | $50k 49,261 shares | +5% | - | |
| 41Moderate | Carl Sailer director buy | $25k 24,631 shares | +22% | - | |
| 45Moderate | Joseph C Scodari director buy | $25k 24,631 shares | +800% | - |
Transactions
Every row filed, 23 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | David P Luci President and CEO | AGrant or award Stock Optionderivative | +37,100 | $0.00 | $0 | 37,100 | Apr 22, 2026 |
| Apr 20, 2026 | Robert J Deluccia director | AGrant or award Stock Optionderivative | +37,100 | $0.00 | $0 | 37,100 | Apr 22, 2026 |
| Apr 20, 2026 | Joseph C Scodari director | AGrant or award Stock Optionderivative | +2,150 | $0.00 | $0 | 2,150 | Apr 22, 2026 |
| Apr 20, 2026 | Thomas L Harrison director | AGrant or award Stock Optionderivative | +2,150 | $0.00 | $0 | 2,150 | Apr 22, 2026 |
| Apr 20, 2026 | James J. Donohue director | AGrant or award Stock Optionderivative | +2,150 | $0.00 | $0 | 2,150 | Apr 22, 2026 |
| Apr 20, 2026 | Jack H Dean director | AGrant or award Stock Optionderivative | +2,150 | $0.00 | $0 | 2,150 | Apr 22, 2026 |
| Apr 20, 2026 | Carl Sailer director | AGrant or award Stock Optionderivative | +2,150 | $0.00 | $0 | 2,150 | Apr 22, 2026 |
| Apr 20, 2026 | Robert G. Shawah Chief Financial Officer | AGrant or award Stock Optionderivative | +25,900 | $0.00 | $0 | 25,900 | Apr 22, 2026 |
| Feb 5, 2025 | Robert J Deluccia director, owner | AGrant or award Stock Optionderivative | +250,000 | $0.00 | $0 | 250,000 | Feb 6, 2025 |
| Feb 5, 2025 | David P Luci President and CEO | AGrant or award Stock Optionderivative | +250,000 | $0.00 | $0 | 250,000 | Feb 6, 2025 |
| Feb 5, 2025 | Robert G. Shawah Chief Financial Officer | AGrant or award Stock Optionderivative | +145,500 | $0.00 | $0 | 145,500 | Feb 6, 2025 |
| Jan 6, 2025 | Jack H Dean director | POpen-market purchase Common Stock | +9,852 | $1.02 | $10,000 | 21,776 | Jan 8, 2025 |
| Jan 6, 2025 | Joseph C Scodari director | POpen-market purchase Common Stock | +24,631 | $1.02 | $25k | 27,708 | Jan 8, 2025 |
| Jan 6, 2025 | Carl Sailer director | POpen-market purchase Common Stock | +24,631 | $1.02 | $25k | 137,183 | Jan 8, 2025 |
| Jan 6, 2025 | David P Luci President and CEO | POpen-market purchase Common Stock | +49,261 | $1.02 | $50k | 1,097,458 | Jan 8, 2025 |
| Jan 6, 2025 | James J. Donohue director | POpen-market purchase Common Stock | +9,852 | $1.02 | $10,000 | 22,352 | Jan 8, 2025 |
| Jan 6, 2025 | Robert J Deluccia director, owner | POpen-market purchase Common Stock | +49,261 | $1.02 | $50k | 1,010,196 | Jan 8, 2025 |
| Jan 6, 2025 | James J. Donohue director | POpen-market purchase Warrants for Common Stockderivative | +9,852 | $0.00 | $0 | 9,852 | Jan 8, 2025 |
| Jan 6, 2025 | Joseph C Scodari director | POpen-market purchase Warrants for Common Stockderivative | +24,631 | $0.00 | $0 | 24,631 | Jan 8, 2025 |
| Jan 6, 2025 | Robert J Deluccia director, owner | POpen-market purchase Warrants for Common Stockderivative | +49,261 | $0.00 | $0 | 49,261 | Jan 8, 2025 |
| Jan 6, 2025 | Carl Sailer director | POpen-market purchase Warrants for Common Stockderivative | +24,631 | $0.00 | $0 | 24,631 | Jan 8, 2025 |
| Jan 6, 2025 | Jack H Dean director | POpen-market purchase Warrants for Common Stockderivative | +9,852 | $0.00 | $0 | 9,852 | Jan 8, 2025 |
| Jan 6, 2025 | David P Luci President and CEO | POpen-market purchase Warrants for Common Stockderivative | +49,261 | $0.00 | $0 | 49,261 | Jan 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jack H Deandirector
- Robert J Delucciadirector, owner
- James J. Donohuedirector
- Thomas L Harrisondirector
- David P LuciPresident and CEO
- Carl Sailerdirector
- Joseph C Scodaridirector
- Robert G. ShawahChief Financial Officer
Questions about ACXP
Answered from the filings on this page, as of the latest one.
Are insiders buying ACXP?
No. In the last 90 days no insider at Acurx Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ACXP on the open market?
Jack H Dean (director) bought $10,000 of ACXP on Jan 6, 2025 and filed the Form 4 on Jan 8, 2025. InsiderTell scored 40 (moderate), with 6 insiders on the same side within 14 days.
How many insiders file Form 4 at Acurx Pharmaceuticals, Inc.?
8 people have filed a Form 4 at Acurx Pharmaceuticals, Inc., among them Jack H Dean (director), Robert J Deluccia (director and 10% owner), James J. Donohue (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.